Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing

AIDS

Volumn 17, Issue 10, 2003, Pages 1463-1471

  Shao, Xing Wu ^a,b   Malmsten, Anders ^b,c   Lennerstrand, Johan ^d   Sönnerborg, Anders ^d   Unge, Torsten ^e   Gronowitz, J Simon ^b   Källander, Clas F R ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Cavidi Tech AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antiretroviral therapy; Antiviral drug resistance; Genotype; HIV 1; HIV 1 drug susceptibility; Phenotype; Reverse transcriptase; Reverse transcriptase inhibitors

Indexed keywords

CELL ENZYME; DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ARTICLE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME IMMOBILIZATION; ENZYME INACTIVATION; ENZYME ISOLATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; PHENOTYPE; PRIORITY JOURNAL; VIRION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; STAVUDINE; THYMINE NUCLEOTIDES; VIRION; ZIDOVUDINE;

EID: 0042869795     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200307040-00007     Document Type: Article

References (27)

1. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994, 91:3911-3915.
2. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195-2199.
3. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000, 14:F83-F93.
4. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. AIDS 2001, 15:309-320.
5. Kellam P, Larder BA. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994, 38:23-30.
6. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44:920-928.
7. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
8. Lennerstrand J, Hertogs K, Stammers DK, Larder BA. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 2001, 75:7202-7205.
9. Lennerstrand J, Stammers DK, Larder BA. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother 2001, 45:2144-2146.
10. Shao XW, Hjalmarsson S, Lennerstrand J, Svennerholm B, Blomberg J, Källander CFR, et al. Application of a colorimetric chaintermination assay for characterization of reverse transcriptase from 3′-azido-2′,3′-deoxythymidine-resistant HIV isolates. Biotechnol Appl Biochem 2002, 35:155-164.
11. Vazquez-Rosales G, Garcia Lerma JG, Yamamoto S, Switzer WM, Havlir D, Folks TM, et al. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. AIDS Res Hum Retroviruses 1999, 15:1191-1200.
12. Lindberg J, Siquardsson S, Löwgren S, Andersson HO, Sahlberg C, Noreen R, et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 2002, 269:1670-1677.
13. Weber J, Grosse F. Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural DNA. Nucl Acids Res 1989, 17:1379-1393.
14. Stammers DK, Somers DO, Ross CK, Kirby I, Ray PH, Wilson JE, et al. Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J Mol Biol 1994, 242:586-588.
15. Malmsten A, Shao XW, Aperia K, Corrigen GE, Sandström E, Källander CF, Leitner T, et al. HIV viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 2003. In press.
16. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998, 37:15908-15917.
17. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999, 4:35-43.
18. Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000, 44:3465-3472.
19. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992, 165:105-110.
20. Vandamme AM, Van Vaerenbergh K, De Clercq E. Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother 1998, 9:187-203.
21. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
22. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, et al. High-level resistance to (-) enantiomeric S2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993, 37:2231-2234.
23. Götte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000, 74:3579-3585.
24. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
25. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998, 102:1769-1775.
26. Larder BA, Stammers DK. Closing in on HIV drug resistance. Nature Struct Biol 1999, 6:103-106.
27. Lennerstrand J, Bergroth T, Shao XW, Van Cauwenberge A, McKenna P, Sönnerborg A. Cross-resistance patterns for HIV-1 muti-nucleoside resistant mutants with mutations associated with re-sensitizatfon to zidovudine. Antivir Ther 2002, 7:43.